Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Signal transduction growth factors: the effective governance of transcription and cellular adhesion in cancer invasion.

Di Domenico M, Giordano A.

Oncotarget. 2017 May 30;8(22):36869-36884. doi: 10.18632/oncotarget.16300. Review.

2.

The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein.

Chen M, Nowak DG, Narula N, Robinson B, Watrud K, Ambrico A, Herzka TM, Zeeman ME, Minderer M, Zheng W, Ebbesen SH, Plafker KS, Stahlhut C, Wang VM, Wills L, Nasar A, Castillo-Martin M, Cordon-Cardo C, Wilkinson JE, Powers S, Sordella R, Altorki NK, Mittal V, Stiles BM, Plafker SM, Trotman LC.

J Cell Biol. 2017 Mar 6;216(3):641-656. doi: 10.1083/jcb.201604025. Epub 2017 Feb 13.

PMID:
28193700
3.

Decreased expression of pseudogene PTENP1 promotes malignant behaviours and is associated with the poor survival of patients with HNSCC.

Liu J, Xing Y, Xu L, Chen W, Cao W, Zhang C.

Sci Rep. 2017 Jan 23;7:41179. doi: 10.1038/srep41179.

4.

Targeting the Mammalian Target of Rapamycin in Lung Cancer.

Vicary GW, Roman J.

Am J Med Sci. 2016 Nov;352(5):507-516. doi: 10.1016/j.amjms.2016.08.014. Epub 2016 Aug 21. Review.

5.

The association of PTEN hypermethylation and breast cancer: a meta-analysis.

Luo S, Chen J, Mo X.

Onco Targets Ther. 2016 Sep 12;9:5643-50. doi: 10.2147/OTT.S111684. eCollection 2016.

6.

EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy.

Chang H, Oh J, Zhang X, Kim YJ, Lee JH, Lee CT, Chung JH, Lee JS.

Onco Targets Ther. 2016 Aug 19;9:5153-62. doi: 10.2147/OTT.S107291. eCollection 2016.

7.

Epigenetics changes caused by the fusion of human embryonic stem cell and ovarian cancer cells.

He K, Qu H, Xu LN, Gao J, Cheng FY, Xiang P, Zhou CQ.

Biosci Rep. 2016 Sep 16;36(5). pii: e00378. doi: 10.1042/BSR20160104. Print 2016 Oct.

8.

Cancer stem cells: progress and challenges in lung cancer.

Templeton AK, Miyamoto S, Babu A, Munshi A, Ramesh R.

Stem Cell Investig. 2014 Apr 15;1:9. doi: 10.3978/j.issn.2306-9759.2014.03.06. eCollection 2014. Review.

9.

Genetic alteration profiling of patients with resected squamous cell lung carcinomas.

Tao D, Han X, Zhang N, Lin D, Wu D, Zhu X, Song W, Shi Y.

Oncotarget. 2016 Jun 14;7(24):36590-36601. doi: 10.18632/oncotarget.9096.

10.

Expression of TAK1/TAB1 expression in non-small cell lung carcinoma and adjacent normal tissues and their clinical significance.

Zhu J, Li Q, He JT, Liu GY.

Int J Clin Exp Pathol. 2015 Dec 1;8(12):15801-7. eCollection 2015.

11.

Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation.

Liao RS, Ma S, Miao L, Li R, Yin Y, Raj GV.

Transl Androl Urol. 2013 Sep;2(3):187-96. doi: 10.3978/j.issn.2223-4683.2013.09.07. Review.

12.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.

Vansteenkiste JF, Canon JL, Braud FD, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC.

J Thorac Oncol. 2015 Sep;10(9):1319-27. doi: 10.1097/JTO.0000000000000607.

13.

COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link.

Bozinovski S, Vlahos R, Anthony D, McQualter J, Anderson G, Irving L, Steinfort D.

Br J Pharmacol. 2016 Feb;173(4):635-48. doi: 10.1111/bph.13198. Epub 2015 Jul 8. Review.

14.

miR-205 regulates A549 cells proliferation by targeting PTEN.

Bai J, Zhu X, Ma J, Wang W.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1175-83. eCollection 2015.

15.

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Yip PY.

Transl Lung Cancer Res. 2015 Apr;4(2):165-76. doi: 10.3978/j.issn.2218-6751.2015.01.04. Review.

16.

PTEN: Multiple Functions in Human Malignant Tumors.

Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F, Ciuffreda L.

Front Oncol. 2015 Feb 16;5:24. doi: 10.3389/fonc.2015.00024. eCollection 2015. Review.

17.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R.

J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405.

18.

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.

Zer A, Leighl N.

Front Oncol. 2014 Nov 25;4:329. doi: 10.3389/fonc.2014.00329. eCollection 2014. Review.

19.

Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.

Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, Chen K, Xiao H, Li H, Tang K, Ye Z, Huang Q, Xu H.

Mol Cancer Ther. 2014 Dec;13(12):3086-97. doi: 10.1158/1535-7163.MCT-14-0245. Epub 2014 Sep 23.

20.

Current concepts on the molecular pathology of non-small cell lung carcinoma.

Fujimoto J, Wistuba II.

Semin Diagn Pathol. 2014 Jul;31(4):306-13. doi: 10.1053/j.semdp.2014.06.008. Epub 2014 Jun 12. Review.

Supplemental Content

Support Center